Home LiteratureArticle Details
PMID: 7958484 Published · ppublish English Journal Article Review

Safe and effective poxvirus vectors--NYVAC and ALVAC.

Developments in biological standardization ·Vol. 82 ·1994-00-00 ·Pages 65-9

Paoletti E, Tartaglia J, Taylor J

Abstract

This paper describes the development and in vitro/in vivo characterization of two highly attenuated recombinant poxvirus vectors. The vectors, NYVAC and ALVAC, exhibit a restricted host range and a greatly enhanced degree of attenuation following inoculation into a range of animal species by a variety of routes. The safety profile of these vectors, together with their demonstrated ability to induce both humoral and cell-mediated immune responses to extrinsic antigens, makes them ideal candidates for use as vaccines in both human and veterinary disease situations.

MeSH Terms
Animals Animals, Newborn Avipoxvirus/genetics,immunology Canaries Defective Viruses/genetics,immunology Genetic Vectors Genome, Viral Humans Mice Mice, Nude Organ Specificity Safety Species Specificity Vaccines, Attenuated Vaccines, Synthetic Vaccinia virus/genetics,immunology Viral Vaccines/immunology
Chemicals
ALVAC vaccine NYVAC vaccine Vaccines, Attenuated Vaccines, Synthetic Viral Vaccines
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Paoletti E
Virogenetics Corporation, Rensselaer Technology Park, Troy, NY.
Tartaglia J
Taylor J
Article Info
Journal
Developments in biological standardization
Abbr.
Dev Biol Stand
ISSN
0301-5149
Published
1994-00-00
Pages
65-9
Language
English
Region
Switzerland
NLM ID
0427140
Subset
IM
External Links
PubMed source
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com